Stock ARTH ARCH THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arch Therapeutics, Inc.

Equities

ARTH

US03939W2089

Market Closed - OTC Markets
Other stock markets
 20:26:07 27/06/2024 BST 		5-day change 1st Jan Change
0.85 USD -11.46% Intraday chart for Arch Therapeutics, Inc. -18.03% -88.26%
06-12 Arch Therapeutics, Inc. announced that it has received $0.15 million in funding CI
05-15 Arch Therapeutics, Inc. announced that it has received $1.85 million in funding CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arch Therapeutics, Inc. announced that it has received $0.15 million in funding
CI
Arch Therapeutics, Inc. announced that it has received $1.85 million in funding
CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
AQ
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
CI
Arch Therapeutics : New Financial Obligation - Form 8-K
PU
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
CI
Arch Therapeutics : New Financial Obligation - Form 8-K
PU
Arch Therapeutics Provides Year End Operational Update
AQ
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
AQ
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
CI
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System
CI
Arch Therapeutics Provides AC5® Commercialization Update
AQ
Arch Therapeutics Completes Financing as Bridge to Uplisting
AQ
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding
CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
CI
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding
CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
CI
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARTH Stock
  4. News Arch Therapeutics, Inc.